Patents by Inventor Josephine Christine Ferdinando
Josephine Christine Ferdinando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9023397Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.Type: GrantFiled: October 6, 2014Date of Patent: May 5, 2015Assignee: Shire LLCInventors: David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
-
Patent number: 8980327Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.Type: GrantFiled: October 6, 2014Date of Patent: March 17, 2015Assignee: Shire LLCInventors: David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
-
Publication number: 20150030695Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.Type: ApplicationFiled: October 6, 2014Publication date: January 29, 2015Inventors: David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
-
Publication number: 20150024013Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Inventors: David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
-
Publication number: 20140178467Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: SHIRE LLCInventors: Roger Withington, David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
-
Publication number: 20090017133Abstract: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of (a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or (b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and (c) compressing the resulting mixture into a tablet or filling up the resulting mixture in an appropriate container.Type: ApplicationFiled: September 24, 2008Publication date: January 15, 2009Applicant: Shire Biochem Inc.Inventors: Robert Paul Haslam, Laura Anna Trespidi, Josephine Christine Ferdinando
-
Patent number: 7465465Abstract: This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.Type: GrantFiled: August 26, 2004Date of Patent: December 16, 2008Assignee: Shire Biochem Inc.Inventors: Robert Paul Haslam, Laura Anna Trespidi, Josephine Christine Ferdinando
-
Publication number: 20080187602Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.Type: ApplicationFiled: April 9, 2008Publication date: August 7, 2008Inventors: Josephine Christine Ferdinando, Petet Neil Davies
-
Patent number: 7381428Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.Type: GrantFiled: November 9, 2005Date of Patent: June 3, 2008Assignee: Shire International Licensing B.V.Inventors: Josephine Christine Ferdinando, Peter Neil Davies
-
Patent number: 6387400Abstract: The invention disclosed herein is a process for increasing the achievable concentration of a pharmaceutically active ingredient relative to fill composition viscosity for dosage units. The process is particularly useful in the preparation of soft gelatin capsules containing ibuprofen, naproxen, indomethacin, and acetaminophen, as the pharmaceutically active ingredient. As a result of the process, lesser quantities of composition ingredients other than the pharmaceutically active ingredient are needed to accomplish the same therapeutically effective dosage, thereby significantly increasing the concentration of the pharmaceutically active ingredient resulting in either a reduction in overall fill volume and dosage unit size or an increase in concentration of pharmaceutically active ingredient per dosage form.Type: GrantFiled: August 29, 2000Date of Patent: May 14, 2002Assignee: R.P. Scherer Technologies, Inc.Inventors: Stephen Charles Tindal, Christopher Clive Webster, Josephine Christine Ferdinando, Jacqueline Carol Lewis
-
Patent number: 6008228Abstract: Compositions which increase the bioavailability of proteinase inhibitors are disclosed. Compositions which include a pharmaceutically acceptable carrier comprising monoglycerides of medium chain-fatty acids are preferred. Preferred medium chain fatty acid glycerides include monoglycerides of saturated C.sub.6 to C.sub.12 fatty acids, preferably C.sub.8 to C.sub.10 fatty acids The pharmaceutically acceptable carrier preferably has an acid value of less than or equal to about 2.5. Preferably, the ratio of monoglycerides of medium chain fatty acid to the proteinase inhibitor is about at least 1.5.Type: GrantFiled: May 7, 1996Date of Patent: December 28, 1999Assignee: Hoffman-La Roche Inc.Inventors: Carole Anne Bailey, Josephine Christine Ferdinando, Navnit Shah